评估新型胰岛素疗法对 2 型糖尿病患者心血管预后的影响:早期系统综述

IF 4.3 3区 医学 Q2 CHEMISTRY, MEDICINAL
Pharmaceuticals Pub Date : 2024-10-03 DOI:10.3390/ph17101322
Teodor Salmen, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana-Adriana Stoica, Marcello Ciaccio, Mohamed El-Tanani, Andrej Janež, Manfredi Rizzo, Florentina Gherghiceanu, Anca Pantea Stoian
{"title":"评估新型胰岛素疗法对 2 型糖尿病患者心血管预后的影响:早期系统综述","authors":"Teodor Salmen, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana-Adriana Stoica, Marcello Ciaccio, Mohamed El-Tanani, Andrej Janež, Manfredi Rizzo, Florentina Gherghiceanu, Anca Pantea Stoian","doi":"10.3390/ph17101322","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background</i> This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. <i>Material and Methods</i> The inclusion criteria were (i) original full-text articles that are randomized control or clinical trials; (ii) published within the last ten years; (iii) published in English; and (iv) conducted on adult human populations. The exclusion criteria were articles deruled on cell cultures or mammals. Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient <i>p</i>-value. Studies were excluded if they were a letter to the editor, expert opinions, case reports, meeting abstracts, or reviews; redundant publications; or needed more precise or complete data. <i>Results</i> The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter). <i>Discussions</i> Further, longer follow-up studies are necessary to verify the long-term CV protection, standardize the specific aspects of CV risk, and compare with subjects without T2DM for a more integrative interpretation of the CV effects independent of the improvement of metabolic activity.</p>","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"17 10","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510241/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.\",\"authors\":\"Teodor Salmen, Claudia-Gabriela Potcovaru, Ioana-Cristina Bica, Rosaria Vincenza Giglio, Angelo Maria Patti, Roxana-Adriana Stoica, Marcello Ciaccio, Mohamed El-Tanani, Andrej Janež, Manfredi Rizzo, Florentina Gherghiceanu, Anca Pantea Stoian\",\"doi\":\"10.3390/ph17101322\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Background</i> This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. <i>Material and Methods</i> The inclusion criteria were (i) original full-text articles that are randomized control or clinical trials; (ii) published within the last ten years; (iii) published in English; and (iv) conducted on adult human populations. The exclusion criteria were articles deruled on cell cultures or mammals. Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient <i>p</i>-value. Studies were excluded if they were a letter to the editor, expert opinions, case reports, meeting abstracts, or reviews; redundant publications; or needed more precise or complete data. <i>Results</i> The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter). <i>Discussions</i> Further, longer follow-up studies are necessary to verify the long-term CV protection, standardize the specific aspects of CV risk, and compare with subjects without T2DM for a more integrative interpretation of the CV effects independent of the improvement of metabolic activity.</p>\",\"PeriodicalId\":20198,\"journal\":{\"name\":\"Pharmaceuticals\",\"volume\":\"17 10\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510241/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/ph17101322\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph17101322","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景 本系统综述注册号为 CRD42024507397,旨在比较雷特鲁肽与替哌肽对心血管(CV)长期保护的已知数据,替哌肽是一种最近被证实对心血管有益的胰岛素。材料与方法 纳入标准为:(i) 随机对照或临床试验的原始全文文章;(ii) 过去十年内发表的文章;(iii) 以英语发表的文章;(iv) 以成人为研究对象的文章。排除标准是以细胞培养或哺乳动物为对象的文章。筛选条件为:(1) 研究对象包括 2 型糖尿病(DM)患者和有 CV 风险的患者;(2) 研究对象包括接受替扎帕肽或瑞他鲁肽治疗的患者;(3) 研究对象提供了足够的信息,如相应的 95% 置信区间或至少足够的 P 值。如果研究是致编辑的信、专家意见、病例报告、会议摘要或综述;多余的出版物;或需要更精确或完整的数据,则排除在外。结果 采用纽卡斯尔-渥太华量表对纳入的 7 项研究进行了偏倚评估,结果显示,这些研究具有异质性,并强调了 2 型糖尿病(T2DM)疗法(血糖、糖化 A1c 血红蛋白、体重、血脂、血压和肾脏参数)对心血管疾病的潜在益处。讨论 有必要进一步开展更长时间的随访研究,以验证对心血管疾病的长期保护作用,规范心血管疾病风险的具体方面,并与未患 T2DM 的受试者进行比较,以便更全面地解释心血管疾病的影响,而不受代谢活动改善的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.

Background This systematic review is registered with CRD42024507397 protocol number and aims to compare the known data about retatrutide on long-term cardiovascular (CV) protection with tirzepatide, an incretin with recent proven CV benefits. Material and Methods The inclusion criteria were (i) original full-text articles that are randomized control or clinical trials; (ii) published within the last ten years; (iii) published in English; and (iv) conducted on adult human populations. The exclusion criteria were articles deruled on cell cultures or mammals. Studies were selected if they (1) included patients with type 2 diabetes mellitus (DM) and CV risk; (2) patients that received either tirzepatide or retatrutide; and (3) provided sufficient information such as the corresponding 95% confidence intervals or at least a sufficient p-value. Studies were excluded if they were a letter to the editor, expert opinions, case reports, meeting abstracts, or reviews; redundant publications; or needed more precise or complete data. Results The seven included studies were assessed for bias with the Newcastle Ottawa scale, heterogenous, and emphasized the potential CV beneficial effect of type 2 DM (T2DM) therapies (glycemia, glycated A1c hemoglobin, body weight, lipid profile, blood pressure and renal parameter). Discussions Further, longer follow-up studies are necessary to verify the long-term CV protection, standardize the specific aspects of CV risk, and compare with subjects without T2DM for a more integrative interpretation of the CV effects independent of the improvement of metabolic activity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pharmaceuticals
Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
6.10
自引率
4.30%
发文量
1332
审稿时长
6 weeks
期刊介绍: Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信